Macrogenics (FRA:M55) Cyclically Adjusted Revenue per Share: €2.08 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:M55 Macrogenics Inc FRA:M55
53 GF Score
Price €3.56
GF Value €3.40
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Macrogenics Cyclically Adjusted Revenue per Share?

Macrogenics FRA:M55 -4.81% 53 Cyclically Adjusted Revenue per Share is €2.08 as of Mar. 2026. GuruFocus rates FRA:M55 with a GF Score™ of 53/100 and a GF Value™ of €3.40 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Macrogenics's adjusted revenue per share for the three months ended in Mar. 2026 was €0.283. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €2.08 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Macrogenics's average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -2.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Macrogenics was -2.60% per year. The lowest was -2.60% per year. And the median was -2.60% per year.

As of today (2026-07-20), Macrogenics's current stock price is €3.56. Macrogenics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €2.08. Macrogenics's Cyclically Adjusted PS Ratio of today is 1.71.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Macrogenics was 7.65. The lowest was 0.46. And the median was 1.61.


Macrogenics  (FRA:M55) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Macrogenics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.56/2.08
=1.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Macrogenics was 7.65. The lowest was 0.46. And the median was 1.61.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Macrogenics Cyclically Adjusted Revenue per Share Related Terms


Macrogenics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Macrogenics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Macrogenics Cyclically Adjusted Revenue per Share Chart

Macrogenics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 2.39 2.32 2.41 2.00

Macrogenics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.08 1.98 2.12 2.00 2.08

FRA:M55 vs IMRX, TRDA, SLNCF: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Macrogenics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Macrogenics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Macrogenics's Cyclically Adjusted PS Ratio falls into.


FRA:M55
53GF Score
Macrogenics Inc FRA:M55
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Macrogenics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Macrogenics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.283/330.2130*330.2130
=0.283

Current CPI (Mar. 2026) = 330.2130.

Macrogenics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.940 241.018 2.658
201609 0.052 241.428 0.071
201612 0.114 241.432 0.156
201703 0.034 243.801 0.046
201706 0.027 244.955 0.036
201709 0.025 246.819 0.033
201712 3.488 246.524 4.672
201803 0.099 249.554 0.131
201806 0.377 251.989 0.494
201809 0.418 252.439 0.547
201812 0.311 251.233 0.409
201903 0.184 254.202 0.239
201906 0.181 256.143 0.233
201909 0.334 256.759 0.430
201912 0.452 256.974 0.581
202003 0.239 258.115 0.306
202006 0.278 257.797 0.356
202009 0.271 260.280 0.344
202012 0.756 260.474 0.958
202103 0.236 264.877 0.294
202106 0.425 271.696 0.517
202109 0.218 274.310 0.262
202112 0.178 278.802 0.211
202203 0.158 287.504 0.181
202206 0.401 296.311 0.447
202209 0.686 296.808 0.763
202212 1.091 296.797 1.214
202303 0.370 301.836 0.405
202306 0.195 305.109 0.211
202309 0.157 307.789 0.168
202312 0.158 306.746 0.170
202403 0.134 312.332 0.142
202406 0.160 314.175 0.168
202409 1.587 315.301 1.662
202412 0.294 315.605 0.308
202503 0.194 319.799 0.200
202506 0.305 322.561 0.312
202509 0.981 324.800 0.997
202512 0.556 324.054 0.567
202603 0.283 330.213 0.283

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €2.08 mean?
Macrogenics (FRA:M55) has a Cyclically Adjusted Revenue per Share of €2.08 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Macrogenics and its competitors.
Is Macrogenics' Cyclically Adjusted Revenue per Share too high?
Macrogenics' current Cyclically Adjusted Revenue per Share is €2.08. Overall, Macrogenics has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' Cyclically Adjusted Revenue per Share compare to IMRX and TRDA?
Macrogenics' Cyclically Adjusted Revenue per Share of €2.08 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Macrogenics and its competitors. Macrogenics's current Cyclically Adjusted Revenue per Share is €2.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Based on GuruFocus' analysis, Macrogenics (FRA:M55) is currently considered Fairly Valued. The stock's GF Value™ is €3.40, compared to a current price of €3.56 — trading 4.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €2.08. Macrogenics' overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current Cyclically Adjusted Revenue per Share is €2.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Macrogenics (FRA:M55) Overvalued in 2026?

Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued. The current stock price of €3.56 is trading 4.7% above its estimated GF Value™ of €3.40. GuruFocus considers Macrogenics to be Fairly Valued.

Key valuation signals for FRA:M55:

  • Cyclically Adjusted Revenue per Share: €2.08
  • GF Value™: €3.40 vs. price of €3.56 (4.7% above fair value)
  • GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Macrogenics Business Description

Other Exchanges MGNX:USA
Address 9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
53GF Score

Get the complete analysis for FRA:M55

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.56
Price
€3.40
GF Value